ED Coding & Reimbursement Alert - 2004 Issue 9
Home Care: OIG OKs Copay Waiver On Diabetes Supplies
Subscribe or sign in to view the full article.
Article Overview
This piece explains a February 2004 HHS Office of Inspector General advisory opinion involving a government-sponsored diabetes study and the approval of copayment waivers for glucose testing equipment and supplies. It also outlines broader compliance considerations for home care providers and durable medical equipment suppliers, including how to evaluate hardship-based waivers, document indigence, and avoid routine or unsupported copay write-offs. The article is relevant to compliance staff, billing professionals, suppliers, and home care organizations seeking general guidance on copayment waiver risk.
Why This Topic Matters
Copayment waiver practices can raise fraud-and-abuse concerns if handled improperly. This article matters because it highlights the kind of limited, fact-specific scenario the OIG viewed favorably and contrasts it with the kinds of routine waiver practices that can create compliance exposure.
What You Will Learn
- How an OIG advisory opinion can affect copayment waiver considerations in a research setting
- What broad compliance factors are discussed for hardship-based copayment waivers
- Why documentation and individualized review are emphasized in waiver decisions
- What general concerns are raised about routine waivers and uncollectible copay write-offs
Who Should Read This
- Home care providers
- Durable medical equipment suppliers
- Billing and coding professionals
- Compliance officers
- Healthcare attorneys
- Revenue cycle staff
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com